

Registry General

Patent Application Advertisements

PATENT AND DESIGN ACT 1930

| GOVERNMENT NOTICE NO.: | 4 |
|------------------------|---|
| | |

Notice is hereby given that person who has grounds of Opposition to the registration of any of the Patent Applications advertised herein according to the Invention claimed under the heading "Patent Applications advertised before Registration" may within two months from the date of this publication, lodge a Notice of Opposition with the Registrar, in writing in duplicate accompanied by a fee of \$45 payable either by cheque made payable to the Accountant General, by cash or by Revenue Stamp obtainable at the Office of the Accountant General.

Please further note that Patent Applications filed in Bermuda for registration are shown with the Official Number accompanied by letters BM. Patent applications registered in the United Kingdom and filed in Bermuda are shown with the Official Number accompanied by the letters UK. Patent Applications registered in the European Union designating the United Kingdom and filed in Bermuda are shown with the Official Number accompanied by the letters EP.

PATENT APPLICATIONS ADVERTISED BEFORE REGISTRATION

Patent No. 662EP

Description: 1-[2-(AMINOMETHYL)BENZYL]-2-THIOXO-1,2,3,5-TETRAHYDRO-4H-PYRROLO[3,2-D]PYRIMIDIN-4-ONES AS INHIBITORS OF MYELOPEROXIDASE

On **12 August 2020**, **ASTRAZENECA AB**, delivered to the Registry of Patents and Designs a signed written declaration of a certain invention, whereof the said **ASTRAZENECA AB**, claims to be the Inventor or Proprietor of an invention for <u>1-[2-(AMINOMETHYL)BENZYL]-2-THIOXO-1,2,3,5-TETRAHYDRO-4H-PYRROLO[3,2-D]PYRIMIDIN-4-ONES AS INHIBITORS OF <u>MYELOPEROXIDASE</u>, together with a specification particularly describing the nature of such invention and the manner in which the same is to be performed. The said **ASTRAZENECA AB** further requests that its name be entered in the Register of Patents as the Proprietor of this Patent.</u>

Patent No. 663EP

Description: ANTIBODIES DIRECTED TO alphaVbeta6 AND USES THEREOF

On **12 August 2020**, **MEDIMMUNE LIMITED**, delivered to the Registry of Patents and Designs a signed written declaration of a certain invention, whereof the said **MEDIMMUNE LIMITED**, claims to be the Inventor or Proprietor of an invention for <u>ANTIBODIES DIRECTED TO alphaVbeta6 AND USES THEREOF</u>, together with a specification particularly describing the nature of such invention and the manner in which the same is to be performed. The said **MEDIMMUNE LIMITED** further requests that its name be entered in the Register of Patents as the Proprietor of this Patent.

Address for Service: Alexanders, Barristers & Attorneys, Belvedere Building, 69 Pitts Bay Road (Ground Floor), Pembroke HM 08, Bermuda.

Patent No. 664EP

Description: ANTI-B7-H1 AND ANTI-CTLA-4 ANTIBODIES FOR TREATING NON-SMALL CELL LUNG CANCER

On **10 September 2020**, **MEDIMMUNE LIMITED**, delivered to the Registry of Patents and Designs a signed written declaration of a certain invention, whereof the said **MEDIMMUNE LIMITED**, claims to be the Inventor or Proprietor of an invention for <u>ANTI-B7-H1 AND ANTI-CTLA-4 ANTIBODIES FOR TREATING NON-SMALL CELL LUNG CANCER</u>, together with a specification particularly describing the nature of such invention and the manner in which the same is to be performed. The said **MEDIMMUNE LIMITED** further requests that its name be entered in the Register of Patents as the Proprietor of this Patent.

Patent No. 665EP

Description: 6,7,8,9-TETRAHYDRO-3H-PYRAZOLO[4,3-F]ISOQUINOLINE DERIVATIVE USEFUL IN THE TREATMENT OF CANCER

On **10 September 2020**, **ASTRAZENECA AB**, delivered to the Registry of Patents and Designs a signed written declaration of a certain invention, whereof the said **ASTRAZENECA AB**, claims to be the Inventor or Proprietor of an invention for <u>6,7,8,9-TETRAHYDRO-3H-PYRAZOLO[4,3-F]ISOQUINOLINE DERIVATIVE USEFUL IN THE TREATMENT OF CANCER</u>, together with a specification particularly describing the nature of such invention and the manner in which the same is to be performed. The said **ASTRAZENECA AB** further requests that its name be entered in the Register of Patents as the Proprietor of this Patent.

Address for Service: Alexanders, Barristers & Attorneys, Belvedere Building, 69 Pitts Bay Road (Ground Floor), Pembroke HM 08, Bermuda.

Patent No. 666EP

Description: ESTROGEN RECEPTOR MODULATORS

On **10 September 2020**, **ASTRAZENECA AB**, delivered to the Registry of Patents and Designs a signed written declaration of a certain invention, whereof the said **ASTRAZENECA AB**, claims to be the Inventor or Proprietor of an invention for <u>ESTROGEN RECEPTOR MODULATORS</u>, together with a specification particularly describing the nature of such invention and the manner in which the same is to be performed. The said **ASTRAZENECA AB** further requests that its name be entered in the Register of Patents as the Proprietor of this Patent.

Patent No. 667EP

Description: THIOACETATE COMPOUNDS, COMPOSITIONS AND METHODS OF USE

On **10 September 2020**, **ARDEA BIOSCIENCES**, **INC**., delivered to the Registry of Patents and Designs a signed written declaration of a certain invention, whereof the said **ARDEA BIOSCIENCES**, **INC**, claims to be the Inventor or Proprietor of an invention for <u>THIOACETATE COMPOUNDS</u>, <u>COMPOSITIONS AND METHODS OF USE</u>, together with a specification particularly describing the nature of such invention and the manner in which the same is to be performed. The said **ARDEA BIOSCIENCES**, **INC** further requests that its name be entered in the Register of Patents as the Proprietor of this Patent.

Address for Service: Alexanders, Barristers & Attorneys, Belvedere Building, 69 Pitts Bay Road (Ground Floor), Pembroke HM 08, Bermuda.

Patent No. 668EP

Description: PYRAZOLE DERIVATIVES USEFUL AS 5-LIPOXYGENASE ACTIVATING PROTEIN (FLAP) INHIBITORS

On **10 September 2020**, **ASTRAZENECA AB**, delivered to the Registry of Patents and Designs a signed written declaration of a certain invention, whereof the said **ASTRAZENECA AB**, claims to be the Inventor or Proprietor of an invention for <u>PYRAZOLE DERIVATIVES USEFUL AS 5-LIPOXYGENASE ACTIVATING PROTEIN (FLAP) INHIBITORS</u>, together with a specification particularly describing the nature of such invention and the manner in which the same is to be performed. The said **ASTRAZENECA AB** further requests that its name be entered in the Register of Patents as the Proprietor of this Patent.

Patent No. 669EP

Description: ANTIBODIES BINDING BETA KLOTHO DOMAIN 2 AND METHODS OF USE THEREOF

On **10 September 2020**, **NGM BIOPHARMACEUTICALS**, **INC.**, delivered to the Registry of Patents and Designs a signed written declaration of a certain invention, whereof the said **NGM BIOPHARMACEUTICALS**, **INC.**, claims to be the Inventor or Proprietor of an invention for <u>ANTIBODIES BINDING BETA KLOTHO DOMAIN 2 AND METHODS OF USE THEREOF</u>, together with a specification particularly describing the nature of such invention and the manner in which the same is to be performed. The said **NGM BIOPHARMACEUTICALS**, **INC.**, further requests that its name be entered in the Register of Patents as the Proprietor of this Patent.

Address for Service: Alexanders, Barristers & Attorneys, Belvedere Building, 69 Pitts Bay Road (Ground Floor), Pembroke HM 08, Bermuda.

Patent No. 670EP

Description: COMPOSITIONS FOR PULMONARY DELIVERY OF LONG-ACTING MUSCARINIC ANTAGONISTS AND LONG-ACTING BETA-2 ADRENERGIC RECEPTOR AGONISTS AND ASSOCIATED METHODS AND SYSTEMS

On **18 September 2020**, **PEARL THERAPEUTICS**, **INC.**, delivered to the Registry of Patents and Designs a signed written declaration of a certain invention, whereof the said **PEARL THERAPEUTICS**, **INC.**, claims to be the Inventor or Proprietor of an invention for <u>COMPOSITIONS FOR PULMONARY DELIVERY OF LONG-ACTING MUSCARINIC ANTAGONISTS AND LONG-ACTING BETA-2 ADRENERGIC RECEPTOR AGONISTS AND ASSOCIATED METHODS AND <u>SYSTEMS</u>, together with a specification particularly describing the nature of such invention and the manner in which the same is to be performed. The said **PEARL THERAPEUTICS**, **INC.**, further requests that its name be entered in the Register of Patents as the Proprietor of this Patent.</u>

Patent No. 671EP

Description: [1,2,4]TRIAZOLO[4,3-B]PYRIDAZINES FOR USE IN THE TREATMENT OF PROLIFERATIVE DISEASES

On **18 September 2020**, **ASTRAZENECA AB**, delivered to the Registry of Patents and Designs a signed written declaration of a certain invention, whereof the said **ASTRAZENECA AB**, claims to be the Inventor or Proprietor of an invention for [1,2,4|TRIAZOLO[4,3-B]PYRIDAZINES FOR USE IN THE TREATMENT OF PROLIFERATIVE DISEASES, together with a specification particularly describing the nature of such invention and the manner in which the same is to be performed. The said **ASTRAZENECA AB**, further requests that its name be entered in the Register of Patents as the Proprietor of this Patent.

Address for Service: Alexanders, Barristers & Attorneys, Belvedere Building, 69 Pitts Bay Road (Ground Floor), Pembroke HM 08, Bermuda.

Patent No. 672EP

Description: ANTIBODY-DRUG CONJUGATE

On **16 October 2020**, **DAIICHI SANKYO COMPANY**, **LIMITED**, delivered to the Registry of Patents and Designs a signed written declaration of a certain invention, whereof the said **DAIICHI SANKYO COMPANY**, **LIMITED**, claims to be the Inventor or Proprietor of an invention for *ANTIBODY-DRUG CONJUGATE*, together with a specification particularly describing the nature of such invention and the manner in which the same is to be performed. The said **DAIICHI SANKYO COMPANY**, **LIMITED**, further requests that its name be entered in the Register of Patents as the Proprietor of this Patent.

Patent No. 673EP

Description: ANTI-HER2 ANTIBODY-DRUG CONJUGATE

On **16 October 2020**, **DAIICHI SANKYO COMPANY**, **LIMITED**, delivered to the Registry of Patents and Designs a signed written declaration of a certain invention, whereof the said **DAIICHI SANKYO COMPANY**, **LIMITED**, claims to be the Inventor or Proprietor of an invention for <u>ANTI-HER2 ANTIBODY-DRUG CONJUGATE</u>, together with a specification particularly describing the nature of such invention and the manner in which the same is to be performed. The said **DAIICHI SANKYO COMPANY**, **LIMITED**, further requests that its name be entered in the Register of Patents as the Proprietor of this Patent.

Address for Service: Alexanders, Barristers & Attorneys, Belvedere Building, 69 Pitts Bay Road (Ground Floor), Pembroke HM 08, Bermuda.

Patent No. 674EP

Description: METHODS AND COMPOSITIONS FOR SUSTAINED DELIVERY OF DRUGS

On **16 October 2020**, **INTRATUS**, **INC.**, delivered to the Registry of Patents and Designs a signed written declaration of a certain invention, whereof the said **INTRATUS**, **INC.**, claims to be the Inventor or Proprietor of an invention for <u>METHODS AND COMPOSITIONS FOR SUSTAINED DELIVERY OF DRUGS</u>, together with a specification particularly describing the nature of such invention and the manner in which the same is to be performed. The said **INTRATUS**, **INC.**, further requests that its name be entered in the Register of Patents as the Proprietor of this Patent.

Patent No. 675EP

Description: PYRROLO[2,3-D]PYRIMIDINYL, PYRROLO[2,3-B]PYRAZINYL AND PYRROLO[2,3-D]PYRIDINYL ACRYLAMIDES

On **16 October 2020**, **PFIZER INC.**, delivered to the Registry of Patents and Designs a signed written declaration of a certain invention, whereof the said **PFIZER INC.**, claims to be the Inventor or Proprietor of an invention for <u>PYRROLO[2,3-D]PYRIMIDINYL</u>, <u>PYRROLO[2,3-B]PYRAZINYL AND PYRROLO[2,3-D]PYRIDINYL ACRYLAMIDES</u>, together with a specification particularly describing the nature of such invention and the manner in which the same is to be performed. The said **PFIZER INC.**, further requests that its name be entered in the Register of Patents as the Proprietor of this Patent.

Address for Service: Alexanders, Barristers & Attorneys, Belvedere Building, 69 Pitts Bay Road (Ground Floor), Pembroke HM 08, Bermuda.

Patent No. 676EP

Description: DELIVERY OF CHOLESTERYL ESTER TO STEROIDOGENIC TISSUES

On **16 October 2020**, **ALPHACORE PHARMA LLC**, delivered to the Registry of Patents and Designs a signed written declaration of a certain invention, whereof the said **ALPHACORE PHARMA LLC**, claims to be the Inventor or Proprietor of an invention for <u>DELIVERY OF CHOLESTERYL ESTER TO STEROIDOGENIC TISSUES</u>, together with a specification particularly describing the nature of such invention and the manner in which the same is to be performed. The said **ALPHACORE PHARMA LLC**, further requests that its name be entered in the Register of Patents as the Proprietor of this Patent.

Patent No. 677EP

Description: AMINOPYRIMIDINYL COMPOUNDS AS JAK INHIBITORS

On **16 October 2020**, **PFIZER INC.**, delivered to the Registry of Patents and Designs a signed written declaration of a certain invention, whereof the said **PFIZER INC.**, claims to be the Inventor or Proprietor of an invention for <u>AMINOPYRIMIDINYL COMPOUNDS AS JAK INHIBITORS</u>, together with a specification particularly describing the nature of such invention and the manner in which the same is to be performed. The said **PFIZER INC.**, further requests that its name be entered in the Register of Patents as the Proprietor of this Patent.

Address for Service: Alexanders, Barristers & Attorneys, Belvedere Building, 69 Pitts Bay Road (Ground Floor), Pembroke HM 08, Bermuda.

Patent No. 678EP

Description: CTLA-4 VARIANTS

On **21 October 2020**, **MEDIMMUNE LIMITED**, delivered to the Registry of Patents and Designs a signed written declaration of a certain invention, whereof the said **MEDIMMUNE LIMITED**, claims to be the Inventor or Proprietor of an invention for <u>CTLA-4 VARIANTS</u>, together with a specification particularly describing the nature of such invention and the manner in which the same is to be performed. The said **MEDIMMUNE LIMITED**, further requests that its name be entered in the Register of Patents as the Proprietor of this Patent.

Patent No. 679EP

Description: PHARMACEUTICAL COMBINATIONS OF AN ANGIOTENSIN RECEPTOR ANTAGONIST AND A NEP INHIBITOR

On **28 October 2020**, **NOVARTIS PHARMA AG**, delivered to the Registry of Patents and Designs a signed written declaration of a certain invention, whereof the said **NOVARTIS PHARMA AG**, claims to be the Inventor or Proprietor of an invention for *PHARMACEUTICAL COMBINATIONS OF AN ANGIOTENSIN RECEPTOR ANTAGONIST AND A NEP INHIBITOR*, together with a specification particularly describing the nature of such invention and the manner in which the same is to be performed. The said **NOVARTIS PHARMA AG**, further requests that its name be entered in the Register of Patents as the Proprietor of this Patent.

Address for Service: Alexanders, Barristers & Attorneys, Belvedere Building, 69 Pitts Bay Road (Ground Floor), Pembroke HM 08, Bermuda.

Patent No. 680EP

Description: (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES AS DIPEPTIDYL PEPTIDASE I INHIBITORS

On 12 November 2020, ASTRAZENECA AB, delivered to the Registry of Patents and Designs a signed written declaration of a certain invention, whereof the said ASTRAZENECA AB, claims to be the Inventor or Proprietor of an invention for (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES AS DIPEPTIDYL PEPTIDASE I INHIBITORS, together with a specification particularly describing the nature of such invention and the manner in which the same is to be performed. The said ASTRAZENECA AB, further requests that its name be entered in the Register of Patents as the Proprietor of this Patent.

Patent No. 681EP

Description: OPTICALLY ACTIVE 2-ARYL CYCLOPROPANE CARBOXAMIDE INTERMEDIATE

On **18 November 2020**, **ASTRAZENECA AB**, delivered to the Registry of Patents and Designs a signed written declaration of a certain invention, whereof the said **ASTRAZENECA AB**, claims to be the Inventor or Proprietor of an invention for <u>OPTICALLY ACTIVE 2-ARYL CYCLOPROPANE CARBOXAMIDE INTERMEDIATE</u>, together with a specification particularly describing the nature of such invention and the manner in which the same is to be performed. The said **ASTRAZENECA AB**, further requests that its name be entered in the Register of Patents as the Proprietor of this Patent.

Address for Service: Alexanders, Barristers & Attorneys, Belvedere Building, 69 Pitts Bay Road (Ground Floor), Pembroke HM 08, Bermuda.

Patent No. 682EP

Description: THERAPEUTIC POLYMERIC NANOPARTICLES AND METHODS OF MAKING AND USING SAME

On **03 December 2020**, **ASTRAZENECA AB**, delivered to the Registry of Patents and Designs a signed written declaration of a certain invention, whereof the said **ASTRAZENECA AB**, claims to be the Inventor or Proprietor of an invention for <u>THERAPEUTIC POLYMERIC NANOPARTICLES AND METHODS OF MAKING AND USING SAME</u>, together with a specification particularly describing the nature of such invention and the manner in which the same is to be performed. The said **ASTRAZENECA AB**, further requests that its name be entered in the Register of Patents as the Proprietor of this Patent.

Patent No. 683EP

Description: PYRROLOPYRROLE COMPOSITIONS AS PYRUVATE KINASE (PKR)

ACTIVATORS

On **03 December 2020**, **FORMA THERAPEUTICS**, **INC.**, delivered to the Registry of Patents and Designs a signed written declaration of a certain invention, whereof the said **FORMA THERAPEUTICS**, **INC.**, claims to be the Inventor or Proprietor of an invention for *PYRROLOPYRROLE COMPOSITIONS AS PYRUVATE KINASE (PKR) ACTIVATORS*, together with a specification particularly describing the nature of such invention and the manner in which the same is to be performed. The said **FORMA THERAPEUTICS**, **INC.**, further requests that its name be entered in the Register of Patents as the Proprietor of this Patent.

Address for Service: Alexanders, Barristers & Attorneys, Belvedere Building, 69 Pitts Bay Road (Ground Floor), Pembroke HM 08, Bermuda.

Patent No. 684EP

Description: COMPOSITIONS FOR RESPIRATORY DELIVERY OF ACTIVE AGENTS AND ASSOCIATED METHODS AND SYSTEMS

On **03 December 2020**, **PEARL THERAPEUTICS**, **INC.**, delivered to the Registry of Patents and Designs a signed written declaration of a certain invention, whereof the said **PEARL THERAPEUTICS**, **INC.**, claims to be the Inventor or Proprietor of an invention for <u>COMPOSITIONS FOR RESPIRATORY DELIVERY OF ACTIVE AGENTS AND ASSOCIATED <u>METHODS AND SYSTEMS</u>, together with a specification particularly describing the nature of such invention and the manner in which the same is to be performed. The said **PEARL THERAPEUTICS**, **INC.**, further requests that its name be entered in the Register of Patents as the Proprietor of this Patent.</u>

Patent No. 685EP

Description: COMPOSITIONS, METHODS & SYSTEMS FOR RESPIRATORY DELIVERY OF TWO OR MORE ACTIVE AGENTS

On **03 December 2020**, **PEARL THERAPEUTICS**, **INC.**, delivered to the Registry of Patents and Designs a signed written declaration of a certain invention, whereof the said **PEARL THERAPEUTICS**, **INC.**, claims to be the Inventor or Proprietor of an invention for <u>COMPOSITIONS</u>, <u>METHODS & SYSTEMS FOR RESPIRATORY DELIVERY OF TWO OR MORE ACTIVE AGENTS</u>, together with a specification particularly describing the nature of such invention and the manner in which the same is to be performed. The said **PEARL THERAPEUTICS**, **INC.**, further requests that its name be entered in the Register of Patents as the Proprietor of this Patent.

Address for Service: Alexanders, Barristers & Attorneys, Belvedere Building, 69 Pitts Bay Road (Ground Floor), Pembroke HM 08, Bermuda.

Patent No. 686EP

Description: USE OF PYRAZOLOPYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PI3K RELATED DISORDERS

On **16 December 2020**, **INCYTE HOLDINGS CORPORATION**, delivered to the Registry of Patents and Designs a signed written declaration of a certain invention, whereof the said **INCYTE HOLDINGS CORPORATION**, claims to be the Inventor or Proprietor of an invention for <u>USE OF PYRAZOLOPYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PI3K RELATED DISORDERS</u>, together with a specification particularly describing the nature of such invention and the manner in which the same is to be performed. The said **INCYTE HOLDINGS CORPORATION**, further requests that its name be entered in the Register of Patents as the Proprietor of this Patent.

Patent No. 687EP

Description: USE OF CYCLIC AMIDE DERIVATIVES TO TREAT SLEEP DISORDERS

On **19 October 2020**, **MINERVA NEUROSCIENCES**, **INC.**, delivered to the Registry of Patents and Designs a signed written declaration of a certain invention, whereof the said **MINERVA NEUROSCIENCES**, **INC.**, claims to be the Inventor or Proprietor of an invention for <u>USE OF CYCLIC AMIDE DERIVATIVES TO TREAT SLEEP DISORDERS</u>, together with a specification particularly describing the nature of such invention and the manner in which the same is to be performed. The said **MINERVA NEUROSCIENCES**, **INC.**, further requests that its name be entered in the Register of Patents as the Proprietor of this Patent.

Address for Service: Alexanders, Barristers & Attorneys, Belvedere Building, 69 Pitts Bay Road (Ground Floor), Pembroke HM 08, Bermuda.

Patent No. 688EP

Description: 4-AMINO-2-(1H-PYRAZOLO[3,4-B]PYRIDIN-3-YL)-6-OXO-6,7-DIHYDRO-5H-PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES AND THE RESPECTIVE (1H-INDAZOL-3-YL)DERIVATIVES AS CGMP MODULATORS FOR TREATING CARDIOVASCULAR DISEASES

On **30 December 2020**, **MERCK SHARP & DOHME CORP.**, delivered to the Registry of Patents and Designs a signed written declaration of a certain invention, whereof the said **MERCK SHARP & DOHME CORP.**, claims to be the Inventor or Proprietor of an invention for <u>4-AMINO-2-(1H-PYRAZOLO[3,4-13]PYRIDIN-3-YL)-6-0X0-6,7-DIHYDRO-5H-PYRROLO[2,3-13]PYRIMIDINE DERIVATIVES AND THE RESPECTIVE (1H-INDAZOL-3-YL)DERIVATIVES AS CGMP MODULATORS FOR TREATING CARDIOVASCULAR DISEASES, together with a specification particularly describing the nature of such invention and the manner in which the same is to be performed. The said **MERCK SHARP & DOHME CORP.**, further requests that its name be entered in the Register of Patents as the Proprietor of this Patent.</u>

Patent No. 689EP

Description: MACROCYCLIC MCL1 INHIBITORS FOR TREATING CANCER

On **06 January 2021**, **ASTRAZENECA AB**, delivered to the Registry of Patents and Designs a signed written declaration of a certain invention, whereof the said **ASTRAZENECA AB**, claims to be the Inventor or Proprietor of an invention for <u>MACROCYCLIC MCL1 INHIBITORS FOR TREATING CANCER</u>, together with a specification particularly describing the nature of such invention and the manner in which the same is to be performed. The said **ASTRAZENECA AB**, further requests that its name be entered in the Register of Patents as the Proprietor of this Patent.

Address for Service: Alexanders, Barristers & Attorneys, Belvedere Building, 69 Pitts Bay Road (Ground Floor), Pembroke HM 08, Bermuda.

Patent No. 690EP

Description: EXENDIN FOR TREATING DIABETES AND REDUCING BODY WEIGHT

On **27 January 2021**, **AMYLIN PHARMACEUTICALS**, **LLC** and **ASTRAZENECA PHARMACEUTICALS LP**, delivered to the Registry of Patents and Designs a signed written declaration of a certain invention, whereof the said **AMYLIN PHARMACEUTICALS**, **LLC** and **ASTRAZENECA PHARMACEUTICALS LP**, claims to be the Inventor or Proprietor of an invention for *EXENDIN FOR TREATING DIABETES AND REDUCING BODY WEIGHT*, together with a specification particularly describing the nature of such invention and the manner in which the same is to be performed. The said **AMYLIN PHARMACEUTICALS**, **LLC** and **ASTRAZENECA PHARMACEUTICALS LP**, further requests that its name be entered in the Register of Patents as the Proprietor of this Patent.

Patent No. 691EP

Description: MODIFIED POLYPEPTIDES FOR BISPECIFIC ANTIBODY SCAFFOLDS

On **27 January 2021**, **MEDIMMUNE**, **LLC**, delivered to the Registry of Patents and Designs a signed written declaration of a certain invention, whereof the said **MEDIMMUNE**, **LLC**, claims to be the Inventor or Proprietor of an invention for <u>MODIFIED POLYPEPTIDES FOR BISPECIFIC ANTIBODY SCAFFOLDS</u>, together with a specification particularly describing the nature of such invention and the manner in which the same is to be performed. The said **MEDIMMUNE**, **LLC**, further requests that its name be entered in the Register of Patents as the Proprietor of this Patent.

Address for Service: Alexanders, Barristers & Attorneys, Belvedere Building, 69 Pitts Bay Road (Ground Floor), Pembroke HM 08, Bermuda.

Patent No. 692EP

Description: PHARMACEUTICALLY ACCEPTABLE SALTS OF BETA-GUANIDINOPROPIONIC ACID WITH IMPROVED PROPERTIES AND USES THEREOF

On **27 January 2021**, **RGENIX**, **INC.**, delivered to the Registry of Patents and Designs a signed written declaration of a certain invention, whereof the said **RGENIX**, **INC.**, claims to be the Inventor or Proprietor of an invention for <u>PHARMACEUTICALLY ACCEPTABLE SALTS OF BETAGUANIDINOPROPIONIC ACID WITH IMPROVED PROPERTIES AND USES THEREOF, together with a specification particularly describing the nature of such invention and the manner in which the same is to be performed. The said **RGENIX**, **INC.**, further requests that its name be entered in the Register of Patents as the Proprietor of this Patent.</u>

Patent No. 693EP

Description: CHIMERIC PROTEIN COMPOSED OF NGF ANTAGONIST DOMAIN AND A TNFA ANTAGONIST DOMAIN

On **10 February 2021**, **MEDIMMUNE LIMITED**, delivered to the Registry of Patents and Designs a signed written declaration of a certain invention, whereof the said **MEDIMMUNE LIMITED**, claims to be the Inventor or Proprietor of an invention for <u>CHIMERIC PROTEIN COMPOSED OF NGF ANTAGONIST DOMAIN AND A TNFA ANTAGONIST DOMAIN</u>, together with a specification particularly describing the nature of such invention and the manner in which the same is to be performed. The said **MEDIMMUNE LIMITED**, further requests that its name be entered in the Register of Patents as the Proprietor of this Patent.